Coronary revascularization in ischemic cardiomyopathy

Stephen Westaby1

  • 1Department of Cardiac Surgery, Oxford Heart Centre, John Radcliffe Hospital, Headley Way, Headington, Oxford OX3 9DU, UK. swestaby@ahf.org.uk

Insights

This review explores myocardial hibernation in coronary artery disease, detailing its link to heart failure and the benefits of revascularization for improving left-ventricular function.

Area of Science:

  • Cardiology
  • Cardiovascular Surgery
  • Molecular Biology

Background:

  • Coronary artery disease (CAD) frequently leads to left-ventricular dysfunction.
  • Myocardial hibernation, a state of impaired contractility, is a key mechanism linking CAD to heart failure.
  • Understanding hibernation is crucial for managing heart failure patients with ischemic cardiomyopathy.

Purpose of the Study:

  • To provide a comprehensive overview of myocardial hibernation in the context of coronary artery disease and heart failure.
  • To discuss the molecular mechanisms, pathophysiology, and clinical implications of myocardial hibernation.
  • To outline patient selection criteria and outcomes for revascularization procedures in heart failure patients with viable but dysfunctional myocardium.

Main Methods:

  • Review of existing literature on myocardial hibernation, left-ventricular dysfunction, and revascularization.
  • Discussion of molecular pathways involved in myocardial stunning and hibernation.
  • Analysis of patient selection for revascularization based on myocardial viability assessment.
  • Examination of outcomes and functional recovery following coronary artery bypass grafting (CABG).

Main Results:

  • Myocardial hibernation is a significant contributor to left-ventricular dysfunction and heart failure in CAD patients.
  • Revascularization can improve left-ventricular function and prognosis in selected patients with hibernating myocardium.
  • Functional recovery after CABG is variable and depends on factors like hibernation duration and collateral circulation.

Conclusions:

  • Myocardial viability assessment is essential for identifying CAD patients who may benefit from revascularization.
  • Revascularization offers a therapeutic option for heart failure patients with ischemic cardiomyopathy and hibernating myocardium.
  • Further research into molecular mechanisms may reveal novel therapeutic targets for myocardial hibernation.

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...